News and Trends 28 Sep 2022 Spoonshot on how foodtech can reduce food waste With the International Day of Awareness of Food Loss and Waste just around the corner, Labiotech caught up with Spoonshot co-founder and CEO Kishan Vasani to find out how the foodtech sector can tackle food waste. Spoonshot is a software platform for food and beverage professionals that delivers category intelligence by leveraging data from more […] September 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Watch: Scottish biotech startup looking to sustainable omega-3 production Established in 2016, Edinburgh-headquartered MiAlgae says there is a global threat to oceans caused by overfishing to supply omega-3 oil for human and animal consumption. This prompted the development of a solution through the circular economy. Labiotech visited the company recently to find out more about its operations. Using its biotech platform, MiAlgae uses co-products […] September 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Watch: IntelliDigest using biotech to tackle food waste After obtaining a PhD in environmental engineering, Ifeyinwa Kanu set up IntelliDigest in 2016. Based in Edinburgh, Scotland, at the Heriot-Watt University Business School Incubator, the biotechnology company specializes in food sustainability. The company aims to address the sustainability challenges faced by the entire global food system, including producers, processors, manufacturers, retailers, and consumers. This […] September 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […] September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Promising MND drug slows disease progression Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 New study shows how prostate cancer may start Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 New Bio Studio program collaboration looks to create life science start-ups The BioInnovation Institute (BII), has entered a collaboration with Imperial College London in the U.K. to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research to benefit people and society. Based in Denmark, the BII is an international commercial, […] September 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin Arecor Therapeutics today (September 20) announced positive results from a phase 1 clinical trial of its rapid, concentrated insulin product. The company’s candidate named AT278 is formulated using its Arestat technology and designed to significantly accelerate insulin absorption post injection. This is to enable more effective and convenient management of blood glucose levels in people […] September 20, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 CGT Catapult begins VR training to help ensure future workforce needs A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […] September 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Domainex’ drug shows positive data for treatment of interferonopathies Interferonapathies such as lupus, Sjögren’s syndrome, and scleroderma could be treated effectively after positive human ex-vivo data was produced. Domainex Ltd., carried out an in-house research program to identify inhibitors of protein kinases TBK1 and IKK-epsilon and DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. Disease modifying The […] September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 CHMP recommends approval of Beyfortus for prevention of RSV disease in infants Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of RSV lower respiratory […] September 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email